Literature DB >> 12808075

Inability of outer-surface protein C (OspC)-primed mice to elicit a protective anamnestic immune response to a tick-transmitted challenge of Borrelia burgdorferi.

Robert D Gilmore1, Rendi M Bacon1, Amber M Carpio1, Joseph Piesman1, Marc C Dolan1, M Lamine Mbow1.   

Abstract

A one-inoculation regimen of recombinant outer-surface protein C (OspC), which has been demonstrated to elicit protective immunity against a tick-borne challenge of Borrelia burgdorferi, was administered to outbred mice. Following seroconversion, the serum antibody titre against OspC was allowed to wane with time until there was little or no detection of anti-OspC antibodies by immunoblot. The mice were then challenged with an infectious dose of B. burgdorferi by tick transmission. Eleven of 12 OspC-primed mice subsequently became infected by B. burgdorferi, demonstrating that a protective anamnestic response was not generated in these mice following the introduction of infectious OspC-expressing spirochaetes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12808075     DOI: 10.1099/jmm.0.05068-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  11 in total

1.  Serologic proteome analysis of Borrelia burgdorferi membrane-associated proteins.

Authors:  Andrew J Nowalk; Robert D Gilmore; James A Carroll
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

2.  OspC phylogenetic analyses support the feasibility of a broadly protective polyvalent chimeric Lyme disease vaccine.

Authors:  Christopher G Earnhart; Richard T Marconi
Journal:  Clin Vaccine Immunol       Date:  2007-03-14

3.  Demonstration of OspC type diversity in invasive human lyme disease isolates and identification of previously uncharacterized epitopes that define the specificity of the OspC murine antibody response.

Authors:  Christopher G Earnhart; Eric L Buckles; John Stephen Dumler; Richard T Marconi
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

4.  Enhanced Protective Immunogenicity of Homodimeric Borrelia burgdorferi Outer Surface Protein C.

Authors:  Diane G Edmondson; Sabitha Prabhakaran; Steven J Norris; Amy J Ullmann; Joe Piesman; Marc Dolan; Christian Probst; Christiane Radzimski; Winfried Stöcker; Lars Komorowski
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

5.  Bacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease.

Authors:  Rhonda L LaFleur; Jennifer C Dant; Terri L Wasmoen; Steven M Callister; Dean A Jobe; Steven D Lovrich; Thomas F Warner; O Abdelmagid; Ronald F Schell
Journal:  Clin Vaccine Immunol       Date:  2008-12-03

6.  Comprehensive seroprofiling of sixteen B. burgdorferi OspC: implications for Lyme disease diagnostics design.

Authors:  Larisa Ivanova; Iva Christova; Vera Neves; Miguel Aroso; Luciana Meirelles; Dustin Brisson; Maria Gomes-Solecki
Journal:  Clin Immunol       Date:  2009-07-02       Impact factor: 3.969

7.  Oral immunization with recombinant lactobacillus plantarum induces a protective immune response in mice with Lyme disease.

Authors:  Beatriz del Rio; Raymond J Dattwyler; Miguel Aroso; Vera Neves; Luciana Meirelles; Jos F M L Seegers; Maria Gomes-Solecki
Journal:  Clin Vaccine Immunol       Date:  2008-07-16

8.  Human and Veterinary Vaccines for Lyme Disease.

Authors:  Nathaniel S O'Bier; Amanda L Hatke; Andrew C Camire; Richard T Marconi
Journal:  Curr Issues Mol Biol       Date:  2020-12-08       Impact factor: 2.081

Review 9.  Vaccination against Lyme disease: past, present, and future.

Authors:  Monica E Embers; Sukanya Narasimhan
Journal:  Front Cell Infect Microbiol       Date:  2013-02-12       Impact factor: 5.293

10.  Oral Immunization with OspC Does Not Prevent Tick-Borne Borrelia burgdorferi Infection.

Authors:  Rita Melo; Luciana Richer; Daniel L Johnson; Maria Gomes-Solecki
Journal:  PLoS One       Date:  2016-03-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.